JP2019203015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019203015A5 JP2019203015A5 JP2019141806A JP2019141806A JP2019203015A5 JP 2019203015 A5 JP2019203015 A5 JP 2019203015A5 JP 2019141806 A JP2019141806 A JP 2019141806A JP 2019141806 A JP2019141806 A JP 2019141806A JP 2019203015 A5 JP2019203015 A5 JP 2019203015A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- compound according
- solvate
- diabetes
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164974A JP7280929B2 (ja) | 2016-09-26 | 2021-10-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016187605 | 2016-09-26 | ||
| JP2016187605 | 2016-09-26 | ||
| JP2018540344A JP6567778B2 (ja) | 2016-09-26 | 2017-09-26 | Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540344A Division JP6567778B2 (ja) | 2016-09-26 | 2017-09-26 | Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164974A Division JP7280929B2 (ja) | 2016-09-26 | 2021-10-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019203015A JP2019203015A (ja) | 2019-11-28 |
| JP2019203015A5 true JP2019203015A5 (https=) | 2020-11-05 |
| JP6957564B2 JP6957564B2 (ja) | 2021-11-02 |
Family
ID=61689595
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540344A Active JP6567778B2 (ja) | 2016-09-26 | 2017-09-26 | Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2019141806A Active JP6957564B2 (ja) | 2016-09-26 | 2019-07-31 | Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2021164974A Active JP7280929B2 (ja) | 2016-09-26 | 2021-10-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2023079006A Active JP7602573B2 (ja) | 2016-09-26 | 2023-05-12 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2024213173A Active JP7789886B2 (ja) | 2016-09-26 | 2024-12-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2025244083A Pending JP2026048784A (ja) | 2016-09-26 | 2025-12-10 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540344A Active JP6567778B2 (ja) | 2016-09-26 | 2017-09-26 | Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164974A Active JP7280929B2 (ja) | 2016-09-26 | 2021-10-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2023079006A Active JP7602573B2 (ja) | 2016-09-26 | 2023-05-12 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2024213173A Active JP7789886B2 (ja) | 2016-09-26 | 2024-12-06 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| JP2025244083A Pending JP2026048784A (ja) | 2016-09-26 | 2025-12-10 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
Country Status (38)
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| MA50520A (fr) * | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020234726A1 (en) * | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| JP7360301B2 (ja) | 2019-11-08 | 2023-10-12 | Ｋｙｂ株式会社 | 作動流体供給システム |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| US20230234968A1 (en) * | 2020-06-10 | 2023-07-27 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| WO2022017338A1 (en) | 2020-07-20 | 2022-01-27 | Eccogene (Shanghai) Co., Ltd. | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| WO2022042691A1 (en) | 2020-08-28 | 2022-03-03 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AU2021306414B2 (en) | 2020-09-01 | 2026-01-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| WO2022048665A1 (en) * | 2020-09-07 | 2022-03-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4211139A4 (en) * | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| WO2022076503A1 (en) * | 2020-10-08 | 2022-04-14 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes |
| EP4227299A4 (en) | 2020-10-12 | 2025-04-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE |
| US20240246959A1 (en) | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN116940561A (zh) | 2021-03-22 | 2023-10-24 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| WO2022268152A1 (zh) | 2021-06-24 | 2022-12-29 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| US20240366639A1 (en) * | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023025201A1 (zh) * | 2021-08-24 | 2023-03-02 | 南京明德新药研发有限公司 | 咪唑并环类化合物及其应用 |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4469444A4 (en) * | 2022-01-24 | 2026-01-07 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| CN119343343A (zh) * | 2022-02-09 | 2025-01-21 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| WO2023220109A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
| IL316478A (en) | 2022-05-11 | 2024-12-01 | Lilly Co Eli | GLP1 tablet preparations |
| US20260097037A1 (en) | 2022-09-22 | 2026-04-09 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| CN116003403B (zh) * | 2022-11-20 | 2024-07-23 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| AU2023404652A1 (en) * | 2022-11-28 | 2025-05-01 | The University Of Melbourne | Pharmaceutical combinations and uses thereof |
| KR20250111397A (ko) * | 2022-12-13 | 2025-07-22 | 일라이 릴리 앤드 캄파니 | 제2형 당뇨병 (t2d), 비만, 또는 적어도 하나의 체중 관련된 동반질환이 있는 과체중을 갖는 대상체를 치료하기 위한 오르포르글리프론의 투약 요법 |
| WO2024137426A1 (en) | 2022-12-19 | 2024-06-27 | Eli Lilly And Company | Process to make glp1 ra and intermediates therefor |
| EP4652167A1 (en) * | 2023-01-17 | 2025-11-26 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| JP2025538520A (ja) * | 2023-06-29 | 2025-11-28 | ウェイン バイオテクノロジー カンパニー，リミテッド | Ｇｌｐ－１受容体アゴニスト並びにその調製方法及び使用 |
| CN120574224A (zh) * | 2023-06-30 | 2025-09-02 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| WO2025011664A1 (zh) | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| CN121712771A (zh) * | 2023-07-28 | 2026-03-20 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| TW202521533A (zh) * | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
| WO2025097835A1 (zh) | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| TW202527933A (zh) * | 2023-11-16 | 2025-07-16 | 大陸商西藏海思科製藥有限公司 | 咪唑-2-酮衍生物及其在醫藥上的應用 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| TW202527937A (zh) * | 2023-12-22 | 2025-07-16 | 大陸商石藥集團百克（山東）生物製藥股份有限公司 | 多環化合物及其用途 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| CN117777111A (zh) * | 2023-12-26 | 2024-03-29 | 上海苏博医药科技有限公司 | 一种Orforglipron关键中间体的合成方法及其中间体 |
| KR20250102249A (ko) | 2023-12-27 | 2025-07-07 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| CN120813584A (zh) * | 2024-01-30 | 2025-10-17 | 海创药业股份有限公司 | 一种具有glp-1受体激动剂作用的小分子化合物及其用途 |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| CN120965634A (zh) * | 2024-05-17 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 一种glp-1受体激动剂中间体的制备方法及其用途 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2025259825A1 (en) | 2024-06-12 | 2025-12-18 | Eli Lilly And Company | Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment |
| WO2025261454A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 |
| KR20250179679A (ko) | 2024-06-19 | 2025-12-30 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026007995A1 (zh) * | 2024-07-03 | 2026-01-08 | 成都地奥九泓制药厂 | 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2026012416A1 (zh) * | 2024-07-11 | 2026-01-15 | 江苏德源药业股份有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2026012449A1 (zh) * | 2024-07-12 | 2026-01-15 | 联邦生物科技(珠海横琴)有限公司 | 一种具有glp-1受体激动剂效应的杂环化合物及其应用 |
| WO2026019827A1 (en) | 2024-07-16 | 2026-01-22 | Eli Lilly And Company | Methods for the removal of n-tosyl protecting group |
| WO2026032183A1 (en) * | 2024-08-05 | 2026-02-12 | Rongchang Pharmaceuticals, Ltd. | Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2026052129A1 (zh) * | 2024-09-09 | 2026-03-12 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
| WO2026073512A1 (zh) * | 2024-10-01 | 2026-04-09 | 海创药业股份有限公司 | 一种杂环化合物及其制备方法和制备口服pk特性和长效pk特性的glp-1受体激动剂前药的用途 |
| CN119101040B (zh) * | 2024-11-08 | 2025-03-21 | 杭州澳赛诺医药技术有限公司 | 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法 |
| CN120309500B (zh) * | 2025-06-19 | 2025-08-15 | 南昌大学 | 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法 |
| CN121021503A (zh) * | 2025-07-31 | 2025-11-28 | 仁奎医药科技(北京)有限公司 | 一类具有glp-1受体激动作用的化合物及应用 |
| CN121064191A (zh) * | 2025-08-15 | 2025-12-05 | 福建基诺厚普生物科技有限公司 | 一种奥格列龙半钙盐水合物的制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998438A (en) | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
| AU760771B2 (en) | 1998-04-01 | 2003-05-22 | Janssen Pharmaceutica N.V. | PDE IV inhibiting pyridine derivatives |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| CN1771231B (zh) * | 2002-08-26 | 2011-05-25 | 武田药品工业株式会社 | 钙受体调节性化合物及其用途 |
| DE10360774A1 (de) * | 2003-12-23 | 2005-07-28 | Robert Bosch Gmbh | Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| EA201300152A1 (ru) | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
| US7727983B2 (en) * | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| JP5748659B2 (ja) | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| JP5755217B2 (ja) * | 2009-03-30 | 2015-07-29 | トランステック・ファーマ，エルエルシー | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 |
| EP2452680B1 (en) * | 2009-07-09 | 2019-12-18 | RaQualia Pharma Inc. | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| KR101913135B1 (ko) | 2011-07-15 | 2018-10-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 |
| WO2013086200A1 (en) * | 2011-12-08 | 2013-06-13 | Research Triangle Institute | Composition and method for neuropeptide s receptor (npsr) antagonists |
| EP2953681B1 (en) * | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
| CN103086955B (zh) | 2013-02-19 | 2014-10-15 | 中国医学科学院医药生物技术研究所 | 3-氨基-4-烷氧亚胺基哌啶的制备方法 |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN117645601A (zh) | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| WO2022017338A1 (en) | 2020-07-20 | 2022-01-27 | Eccogene (Shanghai) Co., Ltd. | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
| WO2022049310A1 (en) | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| US20240050531A1 (en) | 2020-12-16 | 2024-02-15 | The Chinese University Of Hong Kong | A method for reversing aging brain functional decline |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
-
2017
- 2017-06-16 JO JOP/2019/0060A patent/JOP20190060A1/ar unknown
- 2017-09-26 PT PT178532206T patent/PT3517538T/pt unknown
- 2017-09-26 EP EP22180270.5A patent/EP4134367A1/en not_active Withdrawn
- 2017-09-26 IL IL287166A patent/IL287166B2/en unknown
- 2017-09-26 US US18/077,060 patent/USRE50455E1/en active Active
- 2017-09-26 JP JP2018540344A patent/JP6567778B2/ja active Active
- 2017-09-26 HU HUE17853220A patent/HUE066583T2/hu unknown
- 2017-09-26 TW TW106132936A patent/TWI753946B/zh active
- 2017-09-26 AU AU2017330733A patent/AU2017330733B2/en active Active
- 2017-09-26 MD MDE20190833T patent/MD3517538T2/ro unknown
- 2017-09-26 PE PE2019000705A patent/PE20190709A1/es unknown
- 2017-09-26 MA MA46286A patent/MA46286B1/fr unknown
- 2017-09-26 DK DK17853220.6T patent/DK3517538T3/da active
- 2017-09-26 TN TNP/2019/000054A patent/TN2019000054A1/en unknown
- 2017-09-26 IL IL319036A patent/IL319036A/en unknown
- 2017-09-26 PL PL17853220.6T patent/PL3517538T3/pl unknown
- 2017-09-26 US US15/759,872 patent/US10858356B2/en not_active Ceased
- 2017-09-26 CN CN201780059135.7A patent/CN109790161B/zh active Active
- 2017-09-26 CR CR20190149A patent/CR20190149A/es unknown
- 2017-09-26 EP EP24154118.4A patent/EP4349840A3/en active Pending
- 2017-09-26 SG SG11201901565VA patent/SG11201901565VA/en unknown
- 2017-09-26 WO PCT/JP2017/034620 patent/WO2018056453A1/ja not_active Ceased
- 2017-09-26 UA UAA201902662A patent/UA125586C2/uk unknown
- 2017-09-26 FI FIEP17853220.6T patent/FI3517538T3/fi active
- 2017-09-26 MX MX2019003488A patent/MX391309B/es unknown
- 2017-09-26 RS RS20240426A patent/RS65398B1/sr unknown
- 2017-09-26 HR HRP20240499TT patent/HRP20240499T1/hr unknown
- 2017-09-26 MY MYPI2019001591A patent/MY199663A/en unknown
- 2017-09-26 EA EA202190802A patent/EA202190802A3/ru unknown
- 2017-09-26 EA EA201990518A patent/EA037989B1/ru not_active IP Right Cessation
- 2017-09-26 CA CA3038479A patent/CA3038479C/en active Active
- 2017-09-26 LT LTEPPCT/JP2017/034620T patent/LT3517538T/lt unknown
- 2017-09-26 ES ES17853220T patent/ES2987676T3/es active Active
- 2017-09-26 EP EP17853220.6A patent/EP3517538B1/en active Active
- 2017-09-26 SI SI201731497T patent/SI3517538T1/sl unknown
- 2017-09-26 KR KR1020197008190A patent/KR102223227B1/ko active Active
-
2019
- 2019-02-19 ZA ZA2019/01070A patent/ZA201901070B/en unknown
- 2019-02-20 IL IL264945A patent/IL264945B/en unknown
- 2019-03-14 CL CL2019000663A patent/CL2019000663A1/es unknown
- 2019-03-20 CO CONC2019/0002595A patent/CO2019002595A2/es unknown
- 2019-03-21 DO DO2019000074A patent/DOP2019000074A/es unknown
- 2019-03-25 SA SA519401409A patent/SA519401409B1/ar unknown
- 2019-03-25 EC ECSENADI201920228A patent/ECSP19020228A/es unknown
- 2019-03-26 MX MX2022004071A patent/MX2022004071A/es unknown
- 2019-03-26 PH PH12019500659A patent/PH12019500659A1/en unknown
- 2019-07-31 JP JP2019141806A patent/JP6957564B2/ja active Active
-
2020
- 2020-08-26 AU AU2020223687A patent/AU2020223687B2/en active Active
- 2020-10-07 US US17/065,122 patent/US11814381B2/en active Active
-
2021
- 2021-10-06 JP JP2021164974A patent/JP7280929B2/ja active Active
-
2022
- 2022-07-13 AU AU2022205222A patent/AU2022205222B2/en active Active
-
2023
- 2023-05-12 JP JP2023079006A patent/JP7602573B2/ja active Active
- 2023-08-11 US US18/448,497 patent/US12187724B2/en active Active
-
2024
- 2024-02-22 US US18/584,177 patent/US12410168B2/en active Active
- 2024-02-22 US US18/584,672 patent/US12331049B2/en active Active
- 2024-08-30 US US18/820,993 patent/US12331050B2/en active Active
- 2024-11-22 US US18/957,166 patent/US20250092041A1/en active Pending
- 2024-12-06 JP JP2024213173A patent/JP7789886B2/ja active Active
-
2025
- 2025-06-24 US US19/247,822 patent/US20260103463A1/en active Pending
- 2025-07-28 US US19/282,736 patent/US20260055105A1/en active Pending
- 2025-12-10 JP JP2025244083A patent/JP2026048784A/ja active Pending
-
2026
- 2026-03-20 AU AU2026202208A patent/AU2026202208A1/en active Pending
- 2026-03-20 AU AU2026202206A patent/AU2026202206A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019203015A5 (https=) | ||
| RU2462456C2 (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| CN1051312C (zh) | 一种噻唑烷衍生物及其制药应用 | |
| JP2024071370A5 (https=) | ||
| CN109996797B (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| JP2020507589A5 (https=) | ||
| WO2023286844A1 (ja) | 抗ウイルス活性等の生理活性を有する化合物 | |
| JP2010502727A (ja) | 血小板過剰を治療するｂｃｌインヒビター | |
| JP2004502670A5 (https=) | ||
| CN1205695A (zh) | N－取代二氧代噻唑烷基苯甲酰胺衍生物及其制备方法 | |
| CA2600203A1 (en) | New salt and polymorphs of a dpp-iv inhibitor | |
| FR2872813A1 (fr) | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| JP2008502614A5 (https=) | ||
| JP2007533722A5 (https=) | ||
| JP2007527919A5 (https=) | ||
| JP2012512186A (ja) | アミドチアゾール誘導体、その製造方法および使用 | |
| JP2010519249A (ja) | ベンゾフラン抗寄生虫剤 | |
| CN1545411A (zh) | 环丙基和环丁基埃坡霉素类似物 | |
| JP2020517619A5 (https=) | ||
| KR20170061615A (ko) | 피마살탄의 신규 염 | |
| JP2017538711A5 (https=) | ||
| CN108368038A (zh) | 作为硝酰基供体的n-羟基磺酰胺衍生物 | |
| JP2010504321A5 (https=) | ||
| JP2008509896A (ja) | 保護化アミノチアゾールのフッ素化方法 | |
| JP2008530242A5 (https=) |